Crackdown On Bad Regenerative Medicine Could Benefit Gene Therapy
Executive Summary
US FDA to offer series of guidances on regenerative product development – and declares gene therapies eligible for RMAT – as enforcement against 'unscrupulous actors' continues.
You may also be interested in...
FDA Ups Pressure On Stem Cell Therapy Makers To Follow Product Approval Rules
US FDA is frustrated that few stem cell therapy makers are seeking regulatory approval of their products during the current enforcement grace period.
Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA
In interview with the Pink Sheet, Commissioner Gottlieb credits career staff, not his leadership, with many of the policy shifts.
Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway
Accelerated approval would help agency monitor gene therapies for durability and off-target effects, US FDA commissioner says.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
